Portugal - português - DGAV (Direção Geral de Alimentação e Veterinária)

msd animal health, lda. - vacina contra o clostridium e a pasteurelose - suspensão injetável - clostridium + pasteurella - ovinos

Portugal - português - DGAV (Direção Geral de Alimentação e Veterinária)

ceva saúde animal - vacina contra o clostridium e a pasteurelose - suspensão injetável - vacinas bacterianas inativadas (incluindo mycoplasma, toxóide e clamídia) - caprinos; ovinos

Portugal - português - DGAV (Direção Geral de Alimentação e Veterinária)

medinfar-sorológico – produtos e equipamentos, s.a. - anatoxina épsilon de clostridium perfringens, tipo d 5.0 ui ; anacultura de clostridium sordellii 100.0 % ; pasteurella multocida, tipo i (roberts) 4.2 10^9 células ; anacultura e anatoxina de clostridium perfringens, tipo a 1.0 ui - suspensão injetável - clostridium + pasteurella - bovinos, caprinos, ovinos

União Europeia - português - EMA (European Medicines Agency)

seqirus s.r.l.  - zoonotic influenza vaccine (h5n1) (surface antigen, inactivated, adjuvanted), influenza virus surface antigens (haemagglutinin and neuraminidase) of strain: a/turkey/turkey/1/05 (h5n1)-like strain (nibrg-23) - influenza a virus, h5n1 subtype - vacinas - active immunisation against h5 subtype of influenza a virus.

Portugal - português - DGAV (Direção Geral de Alimentação e Veterinária)

zoetis portugal, lda - clostridium perfringens 0.0 ; clostridium chauvoei 0.0 ; clostridium novyi 0.0 ; clostridium septicum 0.0 ; clostridium tetani 0.0 ; clostridium sordellii 0.0 ; clostridium haemolyticum 0.0 - suspensão injetável - clostridium - bovinos, ovinos

União Europeia - português - EMA (European Medicines Agency)

novartis vaccines and diagnostics s.r.l. - antígenos de superfície do vírus da gripe (hemaglutinina e neuraminidase) da cepa a / viet nam / 1194/2004 (h5n1) - influenza, human; immunization; disease outbreaks - vacinas - imunização ativa contra o subtipo h5n1 do vírus da influenza a. , , this indication is based on immunogenicity data from healthy subjects from the age of 18 years onwards following administration of two doses of the vaccine containing a/vietnam/1194/2004 (h5n1)-like strain. , , prepandemic influenza vaccine (h5n1) novartis vaccines and diagnostic should be used in accordance with official recommendations.

Portugal - português - DGAV (Direção Geral de Alimentação e Veterinária)

idt biologika gmbh - clostridium perfringens toxoide alpha 125.0 ur/ml ; clostridium perfringens toxoide beta 1 3354.0 ur/ml ; clostridium perfringens toxoide beta 2 770.0 ur/ml - liofilizado e solvente para suspensão injetável - clostridium - suínos (porcas gestantes e porcas nulíparas)

União Europeia - português - EMA (European Medicines Agency)

moderna biotech spain, s.l. - single-stranded, 5’-capped messenger rna (mrna) produced using a cell-free in vitro transcription from the corresponding dna templates, encoding the viral spike (s) protein of sars-cov-2 - covid-19 virus infection - vacinas - spikevax is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older. spikevax bivalent original/omicron ba. 1 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 years of age and older who have previously received at least a primary vaccination course against covid-19. spikevax bivalent original/omicron ba. 4-5 is indicated for active immunisation to prevent covid-19 caused by sars-cov-2 in individuals 6 months of age and older.  spikevax xbb. 5 is indicated for active immunisation to prevent covid 19 caused by sars-cov-2 in individuals 6 months of age and older. the use of this vaccine should be in accordance with official recommendations.

União Europeia - português - EMA (European Medicines Agency)

laboratorios hipra, s.a. - mycoplasma hyopneumoniae, strain 7304 (nexhyon), expressing the capsid protein of porcine circovirus type 2a, inactivated - immunologicals for suidae, inactivated viral and inactivated bacterial vaccines - porcos - for the active immunisation of pigs:to reduce lung lesions associated with porcine enzootic pneumonia caused by mycoplasma hyopneumoniae. also, to reduce the incidence of these lesions (as observed in field studies). to reduce viraemia, virus load in lungs and lymphoid tissues and the duration of the viraemic period associated with diseases caused by porcine circovirus type 2 (pcv2). efficacy against pcv2 genotypes a, b and d has been demonstrated in field studies. to reduce culling rate and the loss of daily weight gain caused by mycoplasma hyopneumoniae and/or pcv2 related diseases (as observed at 6 months of age in field studies). mycoplasma hyopneumoniae: onset of immunity: 3 weeks after vaccinationduration of immunity: 23 weeks after vaccinationporcine circovirus type 2:onset of immunity: 2 weeks after vaccinationduration of immunity: 22 weeks after vaccinationin addition, a reduction in nasal and faecal shedding and the duration of nasal excretion of pcv2 was demonstrated in animals challenged at 4 weeks and at 22 weeks after vaccination.

União Europeia - português - EMA (European Medicines Agency)

ceva santé animale - clostridium perfringens type c, beta1 toxoid / clostridium perfringens, type a, alpha toxoid / clostridium perfringens, type a, beta2 toxoid / escherichia coli, fimbrial adhesin f4ab / escherichia coli, fimbrial adhesin f4ac / escherichia coli, fimbrial adhesin f5 / escherichia coli, fimbrial adhesin f6 - immunologicals for suidae, inactivated bacterial vaccines (including mycoplasma, toxoid and chlamydia) escherichia + clostridium - porcos - for the passive immunisation of progeny by active immunisation of pregnant sows and gilts to reduce:-           clinical signs (severe diarrhoea) and mortality caused by escherichia coli strains expressing the fimbrial adhesins f4ab, f4ac, f5 and f6-           clinical signs (diarrhoea during the first days of life) associated with clostridium perfringens type a expressing alpha and beta 2 toxins-           clinical signs and mortality associated with haemorrhagic and necrotising enteritis caused by clostridium perfringens type c expressing beta1 toxin.